Krystal Biotech Inc (KRYS)
Payables turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cost of revenue | US$ in thousands | 98,401 | 77,735 | 40,391 | 15,063 | 6,691 |
| Payables | US$ in thousands | 4,132 | 3,981 | 8,398 | 2,105 | 1,021 |
| Payables turnover | 23.81 | 19.53 | 4.81 | 7.16 | 6.55 |
December 31, 2023 calculation
Payables turnover = Cost of revenue ÷ Payables
= $98,401K ÷ $4,132K
= 23.81
The payables turnover ratio for Krystal Biotech Inc has shown an increasing trend over the past five years, indicating an improvement in the company's efficiency in managing its accounts payable. The ratio increased from 6.55 in 2019 to 23.81 in 2023, reflecting that the company is paying its suppliers more frequently relative to the previous years.
A higher payables turnover ratio suggests that the company is paying off its suppliers quickly, which could result in favorable relationships with suppliers and potential discounts for early payments. This trend indicates that Krystal Biotech Inc is effectively managing its payables and may have strong liquidity to meet its short-term obligations in a timely manner.
Overall, the increasing trend in payables turnover for Krystal Biotech Inc signifies efficient management of accounts payable, which could positively impact the company's financial health and relationships with suppliers.
Peer comparison
Dec 31, 2023